✦ LIBER ✦

General pharmacology/safety pharmacology: Customers, biologics, and glps

✍ Scribed by Lewis B. Kinter

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 269 KB
Volume: 35
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.430350305

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Update of general pharmacology/safety ph

Update of general pharmacology/safety pharmacology studies in Japan

✍ Kiyoshi Mizuguchi; Kozo Kanai; Toshiji Igarashi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

Pharmacology and safety of phenylpropano

Pharmacology and safety of phenylpropanolamine

✍ David A. Johnson 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 813 KB

Safety pharmacology program for pharmace

Safety pharmacology program for pharmaceuticals

✍ Lewis B. Kinter; Lon W. Dixon 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 405 KB

Safety pharmacology — A critical perspec

Safety pharmacology — A critical perspective

✍ Roger D. Porsolt 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

The present paper critically reviews the notion of safety pharmacology. The term "safety pharmacology" covers those studies carried out to evaluate the risk potential of a novel substance on different biological systems. Tests for other activities could more appropriately come under the heading of "

An FDA perspective on general pharmacolo

An FDA perspective on general pharmacology studies to determine activity and safety

✍ Martin D. Green 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

Manufacturing of Pharmaceutical Proteins

Manufacturing of Pharmaceutical Proteins || Pharmacology and Drug Safety

✍ Behme, Stefan 📂 Article 📅 2009 🏛 Wiley-VCH Verlag GmbH & Co. KGaA 🌐 German ⚖ 226 KB

Risk-benefit evaluation ## Clinical development determines the speed of product development Manufacturing process should be fixed before phase III j139